doi: 10.1111/jdi.12273.
Epub 2014 Sep 15.
Incretin action on bone: An added benefit?
Affiliations
- PMID: 25969710
- PMCID: PMC4420557
- DOI: 10.1111/jdi.12273
Item in Clipboard
Incretin action on bone: An added benefit?
J Diabetes Investig.
2015 May.
No abstract available
Figures
Actions of glucose-dependent insulinotropic polypeptide (GIP) at its target organs. In addition to its well-known effects on pancreatic β-cell and insulin secretion, GIP has been found to have extrapancreatic effects on the brain, and enhancing memory, increasing glucose utilization in muscle, promoting lipogenesis and inflammation in adipose tissue, and increasing bone formation.
Similar articles
-
The safety of incretin-based therapies--review of the scientific evidence.J Clin Endocrinol Metab. 2011 Jul;96(7):2027-31. doi: 10.1210/jc.2011-0599. J Clin Endocrinol Metab. 2011. PMID: 21734003 Review.
-
The incretin system and its role in type 2 diabetes mellitus.Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36. doi: 10.1016/j.mce.2008.08.012. Epub 2008 Aug 20. Mol Cell Endocrinol. 2009. PMID: 18786605 Review.
-
Incretin based therapies for type 2 diabetes mellitus.J Indian Med Assoc. 2008 Jun;106(6):373-4, 383, 388. J Indian Med Assoc. 2008. PMID: 18839649
-
The contribution of incretin hormones to the pathogenesis of type 2 diabetes.Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):433-41. doi: 10.1016/j.beem.2009.03.007. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 19748061 Review.
-
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.Am J Med. 2011 Jan;124(1 Suppl):S3-18. doi: 10.1016/j.amjmed.2010.11.002. Am J Med. 2011. PMID: 21194578 Review.
Cited by
-
Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.Adv Ther. 2019 Dec;36(12):3321-3339. doi: 10.1007/s12325-019-01126-x. Epub 2019 Oct 23. Adv Ther. 2019. PMID: 31646466 Free PMC article. Review.
References
-
- Yabe D, Seino Y. Incretin actions beyond the pancreas: lessons from knockout mice. Curr Opin Pharmacol. 2013;13:946–953. - PubMed
-
- Bollag RJ, Zhong Q, Ding KH, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol. 2001;177:35–41. - PubMed
-
- Mieczkowska A, Irwin N, Flatt PR, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone. 2013;56:337–342. - PubMed
-
- Gaudin-Audrain C, Irwin N, Mansur S, et al. Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice. Bone. 2013;53:221–230. - PubMed
-
- Torekov SS, Harslof T, Rejnmark L, et al. A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab. 2014;99:E729–E733. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
